{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T14:39:10Z","timestamp":1786372750495,"version":"build-2736575974"},"reference-count":41,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CJASN"],"published-print":{"date-parts":[[2017,2]]},"abstract":"\n Background and objectives<\/jats:title>\n We aimed to investigate the benefits and risks of dual antiplatelet therapy (DAPT) after coronary drug-eluting stent (DES) implantation in patients undergoing hemodialysis.<\/jats:p>\n <\/jats:sec>\n \n Design, setting, participants, & measurements<\/jats:title>\n A nested case-control analysis of patients on hemodialysis after receipt of DES and DAPT treatment was conducted using data from Taiwan\u2019s National Health Insurance Research Database for the period 2007\u20132011. Cases of myocardial infarction or death within 1 year after DES implantation were matched one-to-one with control patients. Odds ratios were calculated to compare DAPT continuation with discontinuation. Additionally, a propensity score\u2013adjusted 6-month landmark cohort analysis was also conducted to evaluate the long-term benefits and risks of prolonged (>6 months) compared with \u22646 months of DAPT use. The primary outcomes were death and myocardial infarction. The secondary outcomes were ischemic stroke, revascularization, and major bleeding.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n In the nested case-control analysis, patients who continued DAPT had a lower rate of death or myocardial infarction within 1 year after receipt of a DES (adjusted odds ratio, 0.54; 95% confidence interval, 0.36 to 0.81;\n P<\/jats:italic>\n =0.003), whereas this association became statistically nonsignificant when compared with patients who discontinued DAPT for the period between 6 and 12 months after receipt of a DES (adjusted odds ratio, 1.51; 95% confidence interval, 0.75 to 3.04). In the propensity score\u2013adjusted cohort analysis, >6 months of DAPT use was not associated with different primary or secondary outcomes than shorter-term use.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n Our findings support that the clinical effectiveness of extended DAPT in a hemodialysis population may be tempered after 6 months post-DES implantation.<\/jats:p>\n <\/jats:sec>","DOI":"10.2215\/cjn.04430416","type":"journal-article","created":{"date-parts":[[2017,2,7]],"date-time":"2017-02-07T16:15:21Z","timestamp":1486484121000},"page":"262-271","source":"Crossref","is-referenced-by-count":26,"title":["Dual Antiplatelet Therapy and Clinical Outcomes after Coronary Drug-Eluting Stent Implantation in Patients on Hemodialysis"],"prefix":"10.2215","volume":"12","author":[{"given":"Yung-Tai","family":"Chen","sequence":"first","affiliation":[{"name":"Divisions of *Nephrology and"},{"name":"Institute of Clinical Medicine,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hung-Ta","family":"Chen","sequence":"additional","affiliation":[{"name":"Endocrinology and Metabolism, Department of Medicine, Taipei City Hospital, Heping Fuyou Branch, Taipei, Taiwan;"},{"name":"School of Medicine, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chien-Yi","family":"Hsu","sequence":"additional","affiliation":[{"name":"Institute of Clinical Medicine,"},{"name":"Cardiovascular Research Center, National Yang-Ming University, Taipei, Taiwan;"},{"name":"Division of Cardiology and Cardiovascular Research Center, Department of Internal Medicine, Taipei Medical University Hospital, Taipei, Taiwan;"},{"name":"College of Medicine and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei-Wen","family":"Chao","sequence":"additional","affiliation":[{"name":"College of Medicine and"},{"name":"Department of Anesthesiology, Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu-Chen","family":"Kuo","sequence":"additional","affiliation":[{"name":"School of Medicine, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuo-Ming","family":"Ou","sequence":"additional","affiliation":[{"name":"Institute of Clinical Medicine,"},{"name":"Division of Nephrology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chia-Jen","family":"Shih","sequence":"additional","affiliation":[{"name":"School of Medicine, and"},{"name":"Deran Clinic, Yilan, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2016,11,28]]},"reference":[{"key":"B1-20230813","first-page":"1343","article-title":"The renal patient with coronary artery disease: Current concepts and dilemmas.","volume":"44","author":"Gupta","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"B2-20230813","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1097\/01.ASN.0000069165.79509.42","article-title":"Coronary artery disease in end-stage renal disease: No longer a simple plumbing problem.","volume":"14","author":"Stenvinkel","year":"2003","journal-title":"J Am Soc Nephrol"},{"key":"B3-20230813","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1161\/CIRCULATIONAHA.112.001264","article-title":"Long-term survival and repeat coronary revascularization in dialysis patients after surgical and percutaneous coronary revascularization with drug-eluting and bare metal stents in the United States.","volume":"127","author":"Shroff","year":"2013","journal-title":"Circulation"},{"key":"B4-20230813","doi-asserted-by":"crossref","first-page":"165","DOI":"10.4065\/mcp.2009.0314","article-title":"Use of drug-eluting stents in patients with coronary artery disease and renal insufficiency.","volume":"85","author":"El-Menyar","year":"2010","journal-title":"Mayo Clin Proc"},{"key":"B5-20230813","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1016\/j.jacc.2011.06.056","article-title":"Safety and efficacy of drug-eluting stents in older patients with chronic kidney disease: A report from the linked CathPCI Registry-CMS claims database.","volume":"58","author":"Tsai","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"B6-20230813","first-page":"e574","article-title":"2011 ACCF\/AHA\/SCAI guideline for percutaneous coronary intervention: A report of the American College of Cardiology Foundation\/American Heart Association Task Force on practice guidelines and the Society for Cardiovascular Angiography and Interventions.","volume":"124","author":"Levine","year":"2011","journal-title":"Circulation"},{"key":"B7-20230813","first-page":"e344","article-title":"2014 AHA\/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: A report of the American College of Cardiology\/American Heart Association Task Force on practice guidelines.","volume":"130","author":"Amsterdam","year":"2014","journal-title":"Circulation"},{"key":"B8-20230813","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1161\/CIRCULATIONAHA.115.021158","article-title":"Individualizing duration of dual antiplatelet therapy after acute coronary syndrome or percutaneous coronary intervention.","volume":"133","author":"Bagai","year":"2016","journal-title":"Circulation"},{"key":"B9-20230813","first-page":"e156","article-title":"Duration of dual antiplatelet therapy: A systematic review for the 2016 ACC\/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: A report of the American College of Cardiology\/American Heart Association Task Force on clinical practice guidelines.","volume":"134","author":"Bittl","year":"2016","journal-title":"Circulation"},{"key":"B10-20230813","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1038\/ki.2011.223","article-title":"Cardiovascular disease in chronic kidney disease. A clinical update from Kidney Disease: Improving Global Outcomes (KDIGO).","volume":"80","author":"Herzog","year":"2011","journal-title":"Kidney Int"},{"key":"B11-20230813","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/j.jacc.2007.10.040","article-title":"Periprocedural bleeding and 1-year outcome after percutaneous coronary interventions: Appropriateness of including bleeding as a component of a quadruple end point.","volume":"51","author":"Ndrepepa","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"B12-20230813","doi-asserted-by":"crossref","first-page":"2556","DOI":"10.1016\/j.jacc.2009.09.076","article-title":"A risk score to predict bleeding in patients with acute coronary syndromes.","volume":"55","author":"Mehran","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"B13-20230813","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1681\/ASN.2008080824","article-title":"Anticoagulant and antiplatelet usage associates with mortality among hemodialysis patients.","volume":"20","author":"Chan","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"B14-20230813","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1016\/S0140-6736(15)60263-X","article-title":"Mortality in patients treated with extended duration dual antiplatelet therapy after drug-eluting stent implantation: A pairwise and Bayesian network meta-analysis of randomised trials.","volume":"385","author":"Palmerini","year":"2015","journal-title":"Lancet"},{"key":"B15-20230813","doi-asserted-by":"crossref","first-page":"445","DOI":"10.7326\/0003-4819-156-6-201203200-00007","article-title":"Effects of antiplatelet therapy on mortality and cardiovascular and bleeding outcomes in persons with chronic kidney disease: A systematic review and meta-analysis.","volume":"156","author":"Palmer","year":"2012","journal-title":"Ann Intern Med"},{"key":"B16-20230813","doi-asserted-by":"crossref","first-page":"e001356","DOI":"10.1161\/JAHA.114.001356","article-title":"Thienopyridine use after coronary stenting in low income patients enrolled in medicare part D receiving maintenance dialysis.","volume":"3","author":"Chang","year":"2014","journal-title":"J Am Heart Assoc"},{"key":"B17-20230813","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1001\/jamainternmed.2015.3540","article-title":"Nationwide population science: Lessons from the Taiwan National Health Insurance Research Database.","volume":"175","author":"Hsing","year":"2015","journal-title":"JAMA Intern Med"},{"key":"B18-20230813","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1161\/CIRCULATIONAHA.114.012717","article-title":"Long-term clinical outcome of major adverse cardiac events in survivors of infective endocarditis: A nationwide population-based study.","volume":"130","author":"Shih","year":"2014","journal-title":"Circulation"},{"key":"B19-20230813","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1164\/rccm.201406-1170OC","article-title":"Association of postdischarge rehabilitation with mortality in intensive care unit survivors of sepsis.","volume":"190","author":"Chao","year":"2014","journal-title":"Am J Respir Crit Care Med"},{"key":"B20-20230813","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1161\/CIRCULATIONAHA.115.018294","article-title":"Risks of death and stroke in patients undergoing hemodialysis with new-onset atrial fibrillation: A competing-risk analysis of a nationwide cohort.","volume":"133","author":"Shih","year":"2016","journal-title":"Circulation"},{"key":"B21-20230813","doi-asserted-by":"crossref","first-page":"500","DOI":"10.2188\/jea.JE20140076","article-title":"Validation of acute myocardial infarction cases in the national health insurance research database in Taiwan.","volume":"24","author":"Cheng","year":"2014","journal-title":"J Epidemiol"},{"key":"B22-20230813","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1001\/jama.297.2.joc60179","article-title":"Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation.","volume":"297","author":"Eisenstein","year":"2007","journal-title":"JAMA"},{"key":"B23-20230813","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1056\/NEJMoa1001266","article-title":"Duration of dual antiplatelet therapy after implantation of drug-eluting stents.","volume":"362","author":"Park","year":"2010","journal-title":"N Engl J Med"},{"key":"B24-20230813","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1016\/j.jacc.2014.09.008","article-title":"Second-generation drug-eluting stent implantation followed by 6- versus 12-month dual antiplatelet therapy: The SECURITY randomized clinical trial.","volume":"64","author":"Colombo","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"B25-20230813","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation.","volume":"40","author":"Charlson","year":"1987","journal-title":"J Chronic Dis"},{"key":"B26-20230813","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1053\/j.gastro.2010.06.067","article-title":"Histamine2-receptor antagonists are an alternative to proton pump inhibitor in patients receiving clopidogrel.","volume":"139","author":"Wu","year":"2010","journal-title":"Gastroenterology"},{"key":"B27-20230813","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","article-title":"A proportional hazards model for the subdistribution of a competing risk.","volume":"94","author":"Fine","year":"1999","journal-title":"J Am Stat Assoc"},{"key":"B28-20230813","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1093\/eurheartj\/ehu523","article-title":"ISAR-SAFE: A randomized, double-blind, placebo-controlled trial of 6 vs. 12 months of clopidogrel therapy after drug-eluting stenting.","volume":"36","author":"Schulz-Sch\u00fcpke","year":"2015","journal-title":"Eur Heart J"},{"key":"B29-20230813","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1056\/NEJMoa1409312","article-title":"Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents.","volume":"371","author":"Mauri","year":"2014","journal-title":"N Engl J Med"},{"key":"B30-20230813","first-page":"390","article-title":"Long-term dual antiplatelet therapy for secondary prevention of cardiovascular events in the subgroup of patients with previous myocardial infarction: A collaborative meta-analysis of randomized trials.","volume":"37","author":"Udell","year":"2016","journal-title":"Eur Heart J"},{"key":"B31-20230813","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1056\/NEJMoa1311890","article-title":"Cardiovascular risk and events in 17 low-, middle-, and high-income countries.","volume":"371","author":"Yusuf","year":"2014","journal-title":"N Engl J Med"},{"key":"B32-20230813","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1136\/heartjnl-2014-307168","article-title":"Outcomes with prolonged clopidogrel therapy after coronary stenting in patients with chronic kidney disease.","volume":"101","author":"Siddiqi","year":"2015","journal-title":"Heart"},{"key":"B33-20230813","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/j.ahj.2007.10.046","article-title":"The efficacy and safety of short- and long-term dual antiplatelet therapy in patients with mild or moderate chronic kidney disease: Results from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial.","volume":"155","author":"Best","year":"2008","journal-title":"Am Heart J"},{"key":"B34-20230813","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1053\/j.ajkd.2007.07.007","article-title":"Aspirin prescription and outcomes in hemodialysis patients: The Dialysis Outcomes and Practice Patterns Study (DOPPS).","volume":"50","author":"Ethier","year":"2007","journal-title":"Am J Kidney Dis"},{"key":"B35-20230813","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.2215\/CJN.00810209","article-title":"Antiplatelet medications in hemodialysis patients: A systematic review of bleeding rates.","volume":"4","author":"Hiremath","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"B36-20230813","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.amjcard.2012.10.030","article-title":"Benefit of long-term dual anti-platelet therapy in patients treated with drug-eluting stents: From the NHLBI dynamic registry.","volume":"111","author":"Mulukutla","year":"2013","journal-title":"Am J Cardiol"},{"key":"B37-20230813","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1161\/CIRCINTERVENTIONS.111.967257","article-title":"Prolonged clopidogrel use after bare metal and drug-eluting stent placement: The veterans administration drug-eluting stent study.","volume":"5","author":"Faxon","year":"2012","journal-title":"Circ Cardiovasc Interv"},{"key":"B38-20230813","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.jacc.2010.09.032","article-title":"Cardiovascular mortality in chronic kidney disease patients undergoing percutaneous coronary intervention is mainly related to impaired P2Y12 inhibition by clopidogrel.","volume":"57","author":"Morel","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"B39-20230813","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1016\/j.jacc.2009.10.043","article-title":"Impact of chronic kidney disease on platelet function profiles in diabetes mellitus patients with coronary artery disease taking dual antiplatelet therapy.","volume":"55","author":"Angiolillo","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"B40-20230813","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1016\/j.amjcard.2009.06.049","article-title":"A comparison of clopidogrel responsiveness in patients with versus without chronic renal failure.","volume":"104","author":"Park","year":"2009","journal-title":"Am J Cardiol"},{"key":"B41-20230813","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1023\/A:1018758308979","article-title":"A pharmacodynamic study of clopidogrel in chronic hemodialysis patients.","volume":"10","author":"Kaufman","year":"2000","journal-title":"J Thromb Thrombolysis"}],"container-title":["Clinical Journal of the American Society of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/01277230-201702000-00009","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T13:36:33Z","timestamp":1786368993000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/01277230-201702000-00009"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11,28]]},"references-count":41,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.2215\/cjn.04430416","relation":{},"ISSN":["1555-9041","1555-905X"],"issn-type":[{"value":"1555-9041","type":"print"},{"value":"1555-905X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,11,28]]}}}